Intranasal dexmedetomidine for procedural sedation in infants: a retrospective study.

IF 1 Q3 PEDIATRICS
Gianluca Dini, Federica Celi, Maria G Santini, Carla M Semeraro
{"title":"Intranasal dexmedetomidine for procedural sedation in infants: a retrospective study.","authors":"Gianluca Dini, Federica Celi, Maria G Santini, Carla M Semeraro","doi":"10.23736/S2724-5276.25.07768-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Infants undergoing magnetic resonance imaging (MRI) often require pharmacological sedation. Dexmedetomidine is an alpha-2 receptor agonist that is frequently used to sedate children and infants, because the neonatologist can easily adjust sedation depth, the patient maintains spontaneous breathing, and awakens rapidly afterwards. The present study evaluates whether dexmedetomidine could safely be used as the sole sedative for preterm and term-born infants less than 80 weeks' postmenstrual age undergoing diagnostic procedures.</p><p><strong>Methods: </strong>We performed a retrospective monocentric analysis of 50 preterm and term-born infants (<80 weeks' postmenstrual age) who were sedated with dexmedetomidine for a brain MRI from October 2019 to March 2024.</p><p><strong>Results: </strong>Successful imaging was achieved in all cases. The median dexmedetomidine loading dose was 2.75 μg/kg (2-4 μg/kg). Bradycardia was observed in four out of 50 patients (8%) and none of them required atropine.</p><p><strong>Conclusions: </strong>These results suggest that dexmedetomidine can be safely used for procedural sedation in the high-risk cohort of preterm and term-born infants less than 80 weeks' postmenstrual age.</p>","PeriodicalId":56337,"journal":{"name":"Minerva Pediatrics","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-5276.25.07768-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Infants undergoing magnetic resonance imaging (MRI) often require pharmacological sedation. Dexmedetomidine is an alpha-2 receptor agonist that is frequently used to sedate children and infants, because the neonatologist can easily adjust sedation depth, the patient maintains spontaneous breathing, and awakens rapidly afterwards. The present study evaluates whether dexmedetomidine could safely be used as the sole sedative for preterm and term-born infants less than 80 weeks' postmenstrual age undergoing diagnostic procedures.

Methods: We performed a retrospective monocentric analysis of 50 preterm and term-born infants (<80 weeks' postmenstrual age) who were sedated with dexmedetomidine for a brain MRI from October 2019 to March 2024.

Results: Successful imaging was achieved in all cases. The median dexmedetomidine loading dose was 2.75 μg/kg (2-4 μg/kg). Bradycardia was observed in four out of 50 patients (8%) and none of them required atropine.

Conclusions: These results suggest that dexmedetomidine can be safely used for procedural sedation in the high-risk cohort of preterm and term-born infants less than 80 weeks' postmenstrual age.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
0.00%
发文量
294
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信